EUCTR2009-016509-41-IT进行中（未招募）不适用
A double-blind placebo controlled randomized trial of PF-804 in patients with incurable stage IIIB/IV non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease.
WWCR, WORLDWIDE CLINICAL RESEARCH0 个研究点目标入组 720 人开始时间: 2011年12月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of non-small cell carcinoma of the lung; Patients must have evidence of disease, but measurable disease is not mandatory. (to be considered evaluable for complete or partial response assessment, patients must have at least one measurable lesion as follows: X-ray >or= 20 mm Spiral CT scan or physical exam >or= 10 mm; Male or female, 18 years of age or older; ECOG performance status of 0, 1, 2 or 3 (patients with performance status of 3 are eligible providing that the investigator attests that the patient has a reasonable life expectancy (>or= 6 weeks); Adequate renal (Creatinine <1.5 upper limit of normal) and hepatic (total bilirubin < 1.5 upper limit of normal; ALT (SGPT) < 2.5 times the upper limit of normal. Note: If clearly attributable to liver metastasis, ALT (SGPT) values < 5 times the upper limit of normal are permitted) within 14 days prior to randomization. (if anemic, patients should be asymptomatic and should not be decompensated); Previous Therapy (see § 5.1.6 of the protocol study); Patient able and willing to complete the quality of life questionnaires; Written patient consent; Patients availability for treatment and follow-up; treatment begins within 2 working day of patient randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients receiving concurrent treatment with other experimental drugs or anti-cancer therapy; Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, should have a LVEF > 50%; Patients with untreated brain or meningeal metastases or treated with corticosteroids at least 1 week prior to randomization; Patients with active or uncontrolled infections, or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol, including: severe dry eye syndrome, keratoconjunctivitis sicca, Sjogren s syndrome, severe exposure keratopathy, disorders that might increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, neutrophilic keratitis), uncontrolled inflammatory gastrointestinal diseases (Crohn's, ulcerative colitis etc), prior pneumonitis/ILD secondary to EGFR inhibitors, mean QTc > 470 msec or history of familial long QT syndrome, drugs that are highly dependent on CYP2D6 for metabolism (see § 5.2.6 of the protocol study), pregnancy or inadequate contraception.
研究者
相似试验
尚未招募
不适用
A randomized double-blind placebo controlled trial on the effect of magnesium oxide in patients with chronic constipatioChronic constipation diadnosed by Rome IV criteriaJPRN-UMIN000028973Hyogo College of Medicine34
尚未招募
Unknown
nderstanding the effect of probiotics consumption in improving the Atopic Dermatitis diseaseCTRI/2024/06/068558nique Biotech Ltd.
进行中（未招募）
不适用
A randomized double-blind placebo controlled trial evaluating the effect of esomeprazole (nexiam) 40 mg twice daily in subjects with chronic unexplained coughgastroesophageal reflux and chronic coughMedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDMedDRA version: 9.1Level: LLTClassification code 10066656Term: Chronic coughEUCTR2009-012505-18-BEZLeuven
已完成
不适用
A randomized double-blind placebo controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT-colonographylarge bowel cancer1001793410017991colorectal cancerNL-OMON35816Academisch Medisch Centrum90
尚未招募
不适用
A randomized double-blind placebo controlled trial on the effect of stimulative laxative and osmotic laxative in patients with chronic constipatioChronic constipation siagnosed by RomeIV criteriaJPRN-UMIN000036519Hyogo College of Medicine90